Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Pandemic Influenza-Pipeline Review, H1 2015

Pandemic Influenza-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Pandemic Influenza-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Pandemic Influenza-Pipeline Review, H1 2015', provides an overview of the Pandemic Influenza's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pandemic Influenza, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pandemic Influenza and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Pandemic Influenza

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Pandemic Influenza and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Pandemic Influenza products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Pandemic Influenza pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Pandemic Influenza

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Pandemic Influenza pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Pandemic Influenza Overview 8

Therapeutics Development 9

Pipeline Products for Pandemic Influenza-Overview 9

Pipeline Products for Pandemic Influenza-Comparative Analysis 10

Pandemic Influenza-Therapeutics under Development by Companies 11

Pandemic Influenza-Therapeutics under Investigation by Universities/Institutes 15

Pandemic Influenza-Pipeline Products Glance 16

Clinical Stage Products 16

Early Stage Products 17

Unknown Stage Products 18

Pandemic Influenza-Products under Development by Companies 19

Pandemic Influenza-Products under Investigation by Universities/Institutes 22

Pandemic Influenza-Companies Involved in Therapeutics Development 23

AIMM Therapeutics B.V. 23

AltraVax Inc. 24

AmVac AG 25

Big DNA Ltd. 26

BioDiem Ltd 27

Celltrion, Inc. 28

Cilian AG 29

Codagenix, Inc. 30

ContraFect Corporation 31

Emergent BioSolutions Inc. 32

GlaxoSmithKline plc 33

Hemispherx Biopharma, Inc. 34

Immunovaccine, Inc. 35

Johnson & Johnson 36

Medicago Inc. 37

NanoBio Corporation 38

Novartis AG 39

Novavax, Inc. 40

OPKO Health, Inc. 41

PDS Biotechnology Corporation 42

PeptiVir, Inc. 43

Protein Sciences Corporation 44

Sinovac Biotech Ltd. 45

Sirnaomics, Inc. 46

TaiGen Biotechnology Co., Ltd. 47

TechnoVax, Inc. 48

Theraclone Sciences, Inc. 49

TSRL, Inc. 50

UMN Pharma Inc. 51

VaxInnate Corporation 52

Pandemic Influenza-Therapeutics Assessment 53

Assessment by Monotherapy Products 53

Assessment by Combination Products 54

Assessment by Target 55

Assessment by Mechanism of Action 57

Assessment by Route of Administration 59

Assessment by Molecule Type 61

Drug Profiles 63

A-06-Drug Profile 63

Alferon LDO-Drug Profile 64

AMV-411-Drug Profile 65

BDNA-002-Drug Profile 66

Bispecific Monoclonal Antibody to Inhibit Hemagglutinin for Seasonal and Pandemic Influenza-Drug Profile 67

CF-404-Drug Profile 68

CiFlu-Drug Profile 69

CTP-25-Drug Profile 71

CTP-27-Drug Profile 72

flu pandemic (H5N1) vaccine-Drug Profile 73

IKT-041-Drug Profile 74

influenza (H5) vaccine-Drug Profile 75

influenza [H7N9] virus like particle vaccine + Glucopyranosyl Lipid A Adjuvant-Drug Profile 76

influenza [strain H5N1] (monovalent) vaccine-Drug Profile 77

influenza [strain H7N9] (monovalent) vaccine-Drug Profile 78

influenza vaccine-Drug Profile 80

influenza vaccine-Drug Profile 81

influenza vaccine-Drug Profile 82

influenza vaccine-Drug Profile 83

Monoclonal Antibodies to Inhibit Hemagglutinin for Pandemic Influenza-Drug Profile 84

Monoclonal Antibodies to Inhibit Hemagglutinin for Seasonal Influenza and Pandemic Influenza-Drug Profile 85

Monoclonal Antibody to Inhibit Hemagglutinin for Influenza-Drug Profile 86

MVAH-5HA-Drug Profile 87

pandemic infleunza vaccine-Drug Profile 88

pandemic influenza [H5N1] vaccine-Drug Profile 89

pandemic influenza [H7N9] (monovalent) vaccine-Drug Profile 90

pandemic influenza vaccine-Drug Profile 91

pandemic influenza vaccine-Drug Profile 92

pandemic influenza vaccine-Drug Profile 93

pandemic influenza vaccine-Drug Profile 94

pandemic influenza vaccine-Drug Profile 95

pandemic influenza vaccine-Drug Profile 96

pandemic influenza vaccine [H5N1]-Drug Profile 97

PDS-0102-Drug Profile 98

PVI-1000-Drug Profile 99

Small Molecules for Influenza-Drug Profile 100

Small Molecules for Influenza-Drug Profile 101

Small Molecules for Pandemic Influenza-Drug Profile 102

STP-702-Drug Profile 103

TCN-032-Drug Profile 104

TSR-026-Drug Profile 106

TSR-462-Drug Profile 107

TVX-002-Drug Profile 108

UMN-0501-Drug Profile 109

UMN-0901-Drug Profile 111

VAX-161-Drug Profile 112

VAX-16101C-Drug Profile 113

VX-787-Drug Profile 114

Pandemic Influenza-Recent Pipeline Updates 115

Pandemic Influenza-Dormant Projects 124

Pandemic Influenza-Discontinued Products 126

Pandemic Influenza-Product Development Milestones 127

Featured News & Press Releases 127

Appendix 131

Methodology 131

Coverage 131

Secondary Research 131

Primary Research 131

Expert Panel Validation 131

Contact Us 131

Disclaimer 132

List of Tables

Number of Products under Development for Pandemic Influenza, H1 2015 12

Number of Products under Development for Pandemic Influenza-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 15

Number of Products under Development by Companies, H1 2015 (Contd..1) 16

Number of Products under Development by Companies, H1 2015 (Contd..2) 17

Number of Products under Investigation by Universities/Institutes, H1 2015 18

Comparative Analysis by Clinical Stage Development, H1 2015 19

Comparative Analysis by Early Stage Development, H1 2015 20

Comparative Analysis by Unknown Stage Development, H1 2015 21

Products under Development by Companies, H1 2015 22

Products under Development by Companies, H1 2015 (Contd..1) 23

Products under Development by Companies, H1 2015 (Contd..2) 24

Products under Investigation by Universities/Institutes, H1 2015 25

Pandemic Influenza-Pipeline by AIMM Therapeutics B.V., H1 2015 26

Pandemic Influenza-Pipeline by AltraVax Inc., H1 2015 27

Pandemic Influenza-Pipeline by AmVac AG, H1 2015 28

Pandemic Influenza-Pipeline by Big DNA Ltd., H1 2015 29

Pandemic Influenza-Pipeline by BioDiem Ltd, H1 2015 30

Pandemic Influenza-Pipeline by Celltrion, Inc., H1 2015 31

Pandemic Influenza-Pipeline by Cilian AG, H1 2015 32

Pandemic Influenza-Pipeline by Codagenix, Inc., H1 2015 33

Pandemic Influenza-Pipeline by ContraFect Corporation, H1 2015 34

Pandemic Influenza-Pipeline by Emergent BioSolutions Inc., H1 2015 35

Pandemic Influenza-Pipeline by GlaxoSmithKline plc, H1 2015 36

Pandemic Influenza-Pipeline by Hemispherx Biopharma, Inc., H1 2015 37

Pandemic Influenza-Pipeline by Immunovaccine, Inc., H1 2015 38

Pandemic Influenza-Pipeline by Johnson & Johnson, H1 2015 39

Pandemic Influenza-Pipeline by Medicago Inc., H1 2015 40

Pandemic Influenza-Pipeline by NanoBio Corporation, H1 2015 41

Pandemic Influenza-Pipeline by Novartis AG, H1 2015 42

Pandemic Influenza-Pipeline by Novavax, Inc., H1 2015 43

Pandemic Influenza-Pipeline by OPKO Health, Inc., H1 2015 44

Pandemic Influenza-Pipeline by PDS Biotechnology Corporation, H1 2015 45

Pandemic Influenza-Pipeline by PeptiVir, Inc., H1 2015 46

Pandemic Influenza-Pipeline by Protein Sciences Corporation, H1 2015 47

Pandemic Influenza-Pipeline by Sinovac Biotech Ltd., H1 2015 48

Pandemic Influenza-Pipeline by Sirnaomics, Inc., H1 2015 49

Pandemic Influenza-Pipeline by TaiGen Biotechnology Co., Ltd., H1 2015 50

Pandemic Influenza-Pipeline by TechnoVax, Inc., H1 2015 51

Pandemic Influenza-Pipeline by Theraclone Sciences, Inc., H1 2015 52

Pandemic Influenza-Pipeline by TSRL, Inc., H1 2015 53

Pandemic Influenza-Pipeline by UMN Pharma Inc., H1 2015 54

Pandemic Influenza-Pipeline by VaxInnate Corporation, H1 2015 55

Assessment by Monotherapy Products, H1 2015 56

Assessment by Combination Products, H1 2015 57

Number of Products by Stage and Target, H1 2015 59

Number of Products by Stage and Mechanism of Action, H1 2015 61

Number of Products by Stage and Route of Administration, H1 2015 63

Number of Products by Stage and Molecule Type, H1 2015 65

Pandemic Influenza Therapeutics-Recent Pipeline Updates, H1 2015 118

Pandemic Influenza-Dormant Projects, H1 2015 127

Pandemic Influenza-Dormant Projects (Contd..1), H1 2015 128

Pandemic Influenza-Discontinued Products, H1 2015 129

List of Figures

Number of Products under Development for Pandemic Influenza, H1 2015 12

Number of Products under Development for Pandemic Influenza-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 14

Number of Products under Investigation by Universities/Institutes, H1 2015 18

Comparative Analysis by Clinical Stage Development, H1 2015 19

Comparative Analysis by Early Stage Products, H1 2015 20

Assessment by Monotherapy Products, H1 2015 56

Number of Products by Top 10 Targets, H1 2015 58

Number of Products by Stage and Top 10 Targets, H1 2015 59

Number of Products by Top 10 Mechanism of Actions, H1 2015 60

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 60

Number of Products by Top 10 Routes of Administration, H1 2015 62

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 62

Number of Products by Top 10 Molecule Types, H1 2015 64

Number of Products by Stage and Top 10 Molecule Types, H1 2015 64

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AIMM Therapeutics B.V.

AltraVax Inc.

AmVac AG

Big DNA Ltd.

BioDiem Ltd

Celltrion, Inc.

Cilian AG

Codagenix, Inc.

ContraFect Corporation

Emergent BioSolutions Inc.

GlaxoSmithKline plc

Hemispherx Biopharma, Inc.

Immunovaccine, Inc.

Johnson & Johnson

Medicago Inc.

NanoBio Corporation

Novartis AG

Novavax, Inc.

OPKO Health, Inc.

PDS Biotechnology Corporation

PeptiVir, Inc.

Protein Sciences Corporation

Sinovac Biotech Ltd.

Sirnaomics, Inc.

TaiGen Biotechnology Co., Ltd.

TechnoVax, Inc.

Theraclone Sciences, Inc.

TSRL, Inc.

UMN Pharma Inc.

VaxInnate Corporation

Pandemic Influenza Therapeutic Products under Development, Key Players in Pandemic Influenza Therapeutics, Pandemic Influenza Pipeline Overview, Pandemic Influenza Pipeline, Pandemic Influenza Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com